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Summary The main subject of this hospital-based case-control study was the possible relationship between
use of combined oral contraceptives (OCs) containing chlormadinone acetate and breast cancer. Analyses were
based on data from 490 cases with newly diagnosed breast cancer and 1,223 controls and were separately
performed for combined OCs with and without chlormadinone. For either of the combined OCs, risk was not
elevated in ever users, did not increase with duration of use and did not change with time since initial exposure
or with time since most recent use. However, the relative risk was increased in current users: RR = 1.72 (0.88,
3.36) for combined OCs with chlormadinone and RR = 1.42 (1.01, 2.00) for combined OCs without chlor-
madinone, which is, however, explained as a screening effect. These results show that chlormadinone as a
constituent of combined OCs does not influence breast cancer risk.
The possible influence of oral contraceptives (OCs) on breast
cancer risk has been investigated in numerous epidemiologic
studies. The results have recently been reviewed (Prentice &
Thomas, 1987). Most studies found no significant alteration
in overall breast cancer risk. Despite these consistent and
reassuring findings, there remains some concern that different
OC formulations or OCs taken at different times in a
woman's reproductive life may enhance the risk of breast
cancer (McPherson et al., 1987). Among other questions are
the possible effects on risk of formulations of varying proges-
togen potency (Pike et al., 1983) or with different types of
oestrogens (Schlesselman et al., 1988).
This study concerns chlormadinone acetate (hereafter re-
ferred to as chlormadinone) as the progestogen component of
OCs. Following treatment with megestrol acetate or chlor-
madinone acetate, breast nodules have been observed in
female beagle dogs (Nelson et al., 1972, 1973; Nelson &
Kelly, 1976; IARC, 1979). Although the conclusions based
on these experiments have been disputed, they led to a
widespread discontinuation of the use of chlormadinone in
OCs. In the former German Democratic Republic (GDR)
only OCs containing chlormadinone were in use up to 1971
when different types were introduced (Nischan & Ebeling,
1984).
This paper reports the results of a case-control study which
is part of the WHO Collaborative Study of Neoplasia and
Steroid Contraceptives (1990) and which was conducted in
the GDR specifically to further investigate the possible role
of OCs containing chlormadinone in the aetiology of breast
cancer.
Material and methods
This investigation, carried out between November 1982 and
July 1986, followed the methods used in the WHO study,
which have been described in detail elsewhere (WHO Col-
laborative Study of Neoplasia and Steroid Contraceptives,
1985). Breast cancer cases were detected by monitoring all
new admissions to the Central Institute of Cancer Research,
Berlin. Cases included all women diagnosed histologically as
having a malignant breast tumour and who were born after
1930.
Controls were selected from among women admitted to the
ear, nose and throat (26%), eye (10%), orthopaedic (49%)
and skin (15%) wards of the district hospital Klinikum
Berlin-Buch, who met the same age criteria as the cases and
who were not admitted for treatment of conditions con-
sidered a priori to possibly alter contraceptive practices (i.e.
circulatory and cardiovascular diseases, diabetes, chronic
renal disease, benign breast disease, previously diagnosed
malignancy, chronic liver disease, and any obstetrical or
gynaecological condition). Controls were not matched to in-
dividual cases, but a sampling procedure was developed to
assure that sufficient controls were included to give a cumu-
lative ratio of approximately two controls per case in each
5-year age group.
A standardised questionnaire was used to obtain infor-
mation on the known and suspected risk factors for breast
cancer, and a complete obstetric and contraceptive history. A
calendar and samples of OCs available in the GDR were
used to facilitate recall of times of use and products taken.
Medical records were reviewed to validate selected items in
the questionnaire, including use of steroid contraceptives. A
pathologist was responsible for diagnosing the cases, and
providing information on the extent of disease at diagnosis
and gross pathology. Slides from all cases were sent to the
WHO reference pathologist (H. Stalsberg, Norway) for
confirmation of diagnosis and uniform histologic
classification according to the WHO Histological Typing of
Breast Tumours (World Health Organisation, 1981).
Questionnaires and forms from the local and reference
pathologists were key entered and edited at the coordinating
centre in Seattle, where statistical analyses were also per-
formed. Combined OCs were classified according to chlor-
madinone content. Relative risks and 95% confidence inter-
vals were computed utilising unconditional logistic regression
(Breslow & Day, 1980). All relative risks were adjusted for
age and, where appropriate, for other variables and use of
OCs of types other than that under consideration.
Results
A total of 502 cases and 1,316 controls were accrued. Three
cases and 93 controls were not interviewed, mainly because
of a short stay in hospital, and nine cases were excluded
because of a prior history of breast cancer. Thus, 490 cases
and 1,223 controls were included in the analysis.
In Table I, relative risks of breast cancer in relation to
various previously recognised risk factors for this disease are
shown. As expected, risk is seen to increase in women with a
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Table I Age distribution of cases and controls and relative risks of breast cancer in
relation to various risk factors
Level No. ofsubjects Relative risk'
Variable ofvariable Cases Controls (95% CI)
Age at interview 20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
Total
Family history of No
cancer Breast
Other
Unknown
Benign breast No
biopsies Yes
Age at menarche < 13
13,14
>14
Nevermenstruated
Test for trend
Total live birth None
1-2
3-4
>4
Test for trend
Age at 1st live birth Never pregnant
Prev. pregnant,
no live births
<20
20-24
25-29
>29
Test for trend'
Menopausal status
Age at menopause
Test for trendb
Premenopausal
Artificial
Natural
Unknown
Nevermenstruated
Premenopausal
<45
45-49
50-54
Unknown
Nevermenstruated
10
25
37
131
175
106
S
490
261
44
155
30
429
61
110
241
139
0
67
326
86
11
51
(0.2%)
(2.0%)
(5.1%)
(7.6%)
(26.7%)
(35.7%)
(21.6%)
(1.0%)
(100%)
0
14
83
123
373
355
257
18
1223
722
38
403
60
1131
92
324
574
323
2
161
777
244
41
118
43
241
576
200
45
16
84
214
91
34
391
59
40
0
0
391
49
29
21
0
0
878
173
169
2
878
174
128
40
1
2
(0.0%)
(1.1%)
(6.8%)
(10.1%)
(30.5%)
(29.0%)
(21.0%)
(1.5%)
(100%)
1.00
3.16
1.04
1.41
1.00
1.70
1.00
1.22
1.21
P<0.05
0.94
1.00
0.80
0.59
P>0.l
1.16
1.05
1.00
1.05
1.27
2.13
P<0.01
1.00
0.64
0.39
1.00
0.55
0.39
0.89
(1.99, 5.00)
(0.82, 1.31)
(0.88, 2.23)
(1.20, 2.39)
(0.93, 1.59)
(0.89, 1.63)
(0.69, 1.29)
(0.60, 1.06)
(0.30, 1.16)
(0.77, 1.76)
(0.56, 1.97)
(0.78, 1.41)
(0.89, 1.80)
(1.27, 3.56)
(0.46, 0.89)
(0.25, 0.58)
(0.39, 0.78)
(0.24, 0.62)
(0.49, 1.63)
P>0.6
aControlled for age; tYTest for trend based on exposed subjects.
family history of breast cancer, and in women who have had
a prior benign breast biopsy. Women of high parity are at
reduced risk of breast cancer and among parous women, risk
is seen to increase with the age at which a woman gives birth
to her first child. Women who have gone through the
menopause are at lower risk of breast cancer than women of
the same age who are still menstruating, and risk is seen to
increase with age at menopause.
Use of any type of OCs (including sequential OCs) was
associated with an age adjusted relative risk (RR) of 0.98
(95% CI = 0.77, 1.24). Risk is also not seen to be altered in
women who ever used combined OCs that contain chlor-
madinone (Table II) and in women who ever used combined
OCs that do not contain chlormadinone (Table III). None of
these relative risk estimates was appreciably altered by con-
trolling for any of the potentially confounding variables
shown in Table I or for use of an IUD. Therefore, unless
otherwise stated, all subsequent relative risk estimates are
controlled only for age and other types of OCs.
As shown in Table II, no appreciable trends in risk were
observed in relation to duration of use, months since first
use, or months since last use of combined OCs that contain
chlormadinone. Similarly, no significant trends in risk in
relation to these features of use were observed for combined
OCs without chlormadinone (Table III). Values for the
relative risks in users of varying duration were not ap-
preciably altered by controlling for either duration of use of
all other combined OCs, or by controlling separately for
duration of use of other types of OCs.
The highest relative risks were observed in women who
had used combined OCs of either type within the previous 3
months (including current users). The possible enhanced risk
in current and recent users were observed for all sizes of
tumour at diagnosis.
Relative risks (and 95% confidence intervals) in women
less than 35 years of age at diagnosis, and in older women,
were respectively 0.94 (0.43, 2.07) and 0.91 (0.73, 1.15) for
those who ever used combined OCs with chlormadinone, and
1.28 (0.33, 4.96) and 1.03 (0.80, 1.32) for those who ever used
combined OCs without chlormadinone.
As shown in Tables IV and V, respectively, neither use of
combined OCs with nor without chlormadinone was assoc-
iated with risk of breast cancer when used by nulliparous
women, or by parous women either before or after the birth
of their first child. Similarly, use of neither type of OCs at a
young age was associated with an increased risk. A modest
increase in risk was observed in women who first used com-
bined products without chlormadinone after the age of 40.
This association was observed in women with tumours of
varying sizes at diagnosis. This relationship is not due to
women over age 40 more frequently being recent users (not
shown). No comparable increase in risk in users after age 40806 K. EBELING
TableII Relative risksofbreastcancerinrelation toeveruse,duration
of use, time since first use, and time since last use of combined oral
contraceptives with chlormadinone
No. ofsubjects Relative riska
Category ofuse Cases Controls (95% CI)
Ever use
No 297 705 1.00
Yes 193 518 0.89 (0.71, 1.12)
Months of use
None or < 1 302 713 1.00
1-12 50 138 0.87 (0.61, 1.24)
13-36 46 155 0.69 (0.48, 1.00)
37-60 40 98 0.98 (0.65, 1.47)
>60 49 110 1.04 (0.72, 1.52)
Unknown 3 9 0.75 (0.20, 2.85)
Test for trend P>0.2
Months since first use
No use 297 705 1.00
1-120 25 74 0.79 (0.49, 1.29)
121-156 44 98 1.10 (0.74, 1.64)
157-180 51 122 1.06 (0.74, 1.54)
181-204 44 132 0.78 (0.53, 1.14)
>204 26 85 0.69 (0.43, 1.10)
Unknown 3 7 0.95 (0.24, 3.76)
Test for trendb P> 0.4
Months since last use
No use 297 705 1.00
Current use or use < 3
mos ago 16 22 1.72 (0.88, 3.36)
4- 96 42 128 0.80 (0.54, 1.18)
97-132 60 128 1.14 (0.80, 1.63)
133-156 37 98 0.95 (0.62, 1.44)
> 156 37 134 0.63 (0.43, 0.94)
Unknown 1 8
Test for trendb P>0.05
aAdjusted for age and use ofother types oforalcontraceptives;"Test
for trend based on exposed subjects.
Table III Relative risks of breast cancer in relation to ever use,
duration ofuse, time sincefirst use, and time since last use ofcombined
oral contraceptives without chlormadinone
No. ofsubjects Relative riska
Category ofuse Cases Controls (95% CI)
Ever use
No 256 624 1.00
Yes 234 599 1.03 (0.81, 1.31)
Months of use
None or <1 260 632 1.00
1-12 30 97 0.79 (0.51, 1.25)
13-36 35 123 0.72 (0.47, 1.10)
37-60 48 105 1.21 (0.81, 1.79)
61-96 69 131 1.38 (0.97, 1.97)
>96 48 128 1.01 (0.69, 1.49)
Unknown 0 7
Test for trend P>0.9
Months since first use
No use 256 624 1.00
1- 96 76 162 1.21 (0.87, 1.68)
97-120 62 138 1.22 (0.84, 1.76)
121-144 58 158 0.98 (0.68, 1.40)
>144 38 137 0.72 (0.48, 1.08)
Unknown 0 4
Test for trendb P<0.05
Months since last use
No use 256 624 1.00
Current use or use < 3
mos ago 82 164 1.42 (1.01, 2.00)
4-36 55 126 1.18 (0.81, 1.71)
37-60 38 92 1.05 (0.69, 1.60)
61-96 35 121 0.76 (0.50, 1.16)
>96 24 91 0.67 (0.41, 1.09)
Unknown 0 5
Test for trendb P<0.01
aAdjusted for age and use ofother types oforal contraceptives;"Test
for trend based on exposed subjects.
Table IV Relative risks of breast cancer in relation to age at first use
and use before and afterfirst live birth, ofcombined oral contraceptives
with chlormadinone
No. ofsubjects Relative risk'
Category of use Cases Controls (95% CI)
Age at first use
No use 297 705 1.00
15-24 29 98 0.79 (0.48, 1.30)
25-29 51 177 0.70 (0.49, 1.02)
30-34 63 128 1.07 (0.76, 1.53)
>34 49 113 0.98 (0.67, 1.42)
Unknown 1 2
Test for trend' P <0.05
First live birth
No use 297 705 1.00
Before 1st live birth 6 36 0.39 (0.16, 0.98)
Only after 1st live birth 172 446 0.92 (0.73, 1.17)
Users without live
birth 15 35 0.97 (0.52, 1.82)
Unknown 0 1
aAdjusted for age and use ofother types oforal contraceptives;"Test
for trend based on exposed subjects.
Table V Relative risksofbreast cancer in relation toageatfirst useand
use before and after first live birth, of combined oral contraceptives
without chlormadinone
No. ofsubjects Relative riska
Category ofuse Cases Controls (95% CI)
Age at first use
No use 256 624 1.00
15-29 54 176 0.73 (0.43, 1.24)
30-34 61 165 0.99 (0.68, 1.44)
35-39 66 169 0.90 (0.64, 1.26)
>40 53 88 1.46 (1.00, 2.13)
Unknown 0 1
Test for trendb P<0.01
First live birth
No use 256 624 1.00
Before 1st live birth 9 30 0.60 (0.24, 1.50)
Only after 1st live birth 209 524 1.06 (0.83, 1.35)
Users without live
birth 16 44 0.77 (0.40, 1.45)
Unknown 0 1
aAdjusted for age and use ofother types oforal contraceptives; bTest
for trend based on exposed subjects.
was observed in association with chlormadinone-containing
combined products.
The joint effect of combined OCs with and without chlor-
madinone on risk was considered, and the estimate of the
risk relative to non-users of either type was not greater for
women who ever used both types (RR = 0.97; 95%
CI= 0.72, 1.13) than for women who used only combined
products with chlormadinone (RR = 0.90; 95% CI = 0.62;
1.29) or for those who only used combined products without
chlormadinone (RR = 1.01; 95% CI = 0.73; 1.41).
Discussion
Progestogens that are derivatives of 17-hydroxyprogesterone
include medroxyprogesterone acetate and chlormadinone ace-
tate. These compounds were shown in some studies to cause
benign and malignant tumours in beagle dogs. Although
both the results of these experiments and their relevance for
human breast cancer have been questioned, these products
were consequently withdrawn from public use as constituents
of OCs in most countries (Vallance & Capel-Edwards, 1971;
Giles et al., 1978; Kwaplen et al., 1980; El Etreby et al., 1979,
El Etreby & Neumann, 1980; Diszfalusy, 1982).
Most combined OCs contain progestogens that are 19-nor-
testosterone derivatives, and these compounds are likely the
constituents that are responsible for the enhanced risk of
thromboembolic phenomenon in users of OCs. ProgestogensORAL CONTRACEPTIVES AND BREAST CANCER 807
that are derived from 17-hydroxyprogesterone may not result
in such adverse cardiovascular effects. If the influence of OCs
that contain these compounds on risks of cancers in humans
is not different or more favourable, than those associated
with OCs that contain 19-nor-testosterone derivatives, then it
would seem prudent to consider reintroducing such formula-
tions for human use. Unfortunately, little information is
available on the influence of such products on cancer risks in
humans.
From 1966 to 1970, the only combined OC available in the
GDR was a product that contained 3.0 mg chlormadinone
and 100tig mestranol. A combined product containing
2.0 mg chlormadinone and 80fig mestranol was introduced
in 1971. A sequential product containing 2.0 mg chlorma-
dinone (taken for 7 days) and 100fig mestranol (taken for 21
days) was introduced in 1970. Combined products without
chlormadinone were first marketed in 1971, and sequentials
without chlormadinone were first made available in 1976.
From 1970 to 1978, the proportion of users who used pro-
ducts with chlormadinone decreased from 100% to 20%
(Nischan & Ebeling, 1984). This variation in exposure pro-
vided a unique opportunity to investigate possible relation-
ships between breast cancer and combined OCs with and
without chlormadinone as the constituent progestogen.
The results from this study are quite likely to be valid.
Selection bias is unlikely to have been a problem because few
eligible cases or controls were not interviewed. Recall bias
was minimised by selection of hospitalised controls, and by
interviewing all study subjects in hospital. In addition, in-
formation on use of OCs that was obtained from interviews
was supplemented by reviewing medical records for 80% of
the women; and this proportion was similar for cases and
controls, and for users of various types of OCs. The
identification of associations between breast cancer and most
of the generally accepted risk factors for this disease provides
further reassurance as to the quality of the data. Further-
more, this study revealed no increased overall risk of breast
cancer associated with use of all types of OCs combined, or
of combined OCs without chlormadinone. This is in accor-
dance with the findings from most recent investigations that
have not been confined to specific ages or other subgroups of
subjects (Lipnick et al., 1986; Ellery et al., 1986; Schlesselman
et al., 1988; La Vecchia et al., 1986; Paul et al., 1986;
Rosenberg et al., 1984; Vessey et al., 1983; Brinton et al.,
1982).
Since the main subject of this investigation was the possi-
ble relationship between use of combined OCs with chlor-
madinone and breast cancer, separate analyses were per-
formed to allow a comparison of results for products with
and without this progestational agent. They showed that
breast cancer risk did not increase with duration of use of
combined OCs with or without chlormadinone. For either of
these products, risk also did not change with time since
initial exposure or with time since most recent use. However,
there appeared to be an increase in risk in current users of
both types of combined products. These findings, if not
spurious, would be consistent with a promotional effect of
OCs on the development of breast cancer.
The increase in risk for current users could, however, have
resulted from a higher rate of screening for breast cancer
among women who are users of OCs. Evidence against this
explanation is the observation that the enhanced risk in
recent users were observed for all sizes of tumour at diag-
nosis. On the other hand, routine mammographic examina-
tion with a higher detection rate of smaller tumours, had not
been widely performed during the study period, and another
study conducted in the GDR showed no statistically
significant differences between size of tumours diagnosed by
chance and by regular physical examination or regular mon-
thly breast self examination (Kloskowski & Ebeling, 1990a;
1990b). Therefore, the fact that the enhanced risk could be
observed for all sizes of tumours is not strong evidence
against the observed associations being a result of more
frequent breast examinations of users than non-users. In fact,
in the GDR, guidelines of the Association of Obstetrics and
Gynaecology advised all gynaecologists prescribing OCs to
perform regular annual physical breast examinations on all
users. Additionally, a higher proportion of cases than con-
trols who were current users of combined OCs had recently
started their use. Therefore, a screening effect seems to be a
more likely explanation for the observed increase in risk in
recent users than a causal relationship between recent use
and breast cancer.
In conclusion, our investigation showed that chlormadi-
none as a constituent of combined OCs does not influence
breast cancer risk.
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